SKLB1028, developed by CSPC ZhongQi Pharmaceutical Technology Co., Ltd., is currently undergoing a Phase I/II clinical trial to evaluate its safety, tolerability, and pharmacokinetics when combined with the standard '7+3' chemotherapy regimen in patients with newly diagnosed AML. The trial is particularly focused on patients with FLT3 mutations, a significant subset of AML that represents a substantial market opportunity due to the high unmet need for effective therapies. The competitive landscape includes other FLT3 inhibitors such as midostaurin and gilteritinib, which have established their efficacy in this patient population. Successful outcomes from this trial could position SKLB1028 as a viable treatment option, potentially enhancing CSPC's portfolio in the oncology space and providing a strategic advantage in the growing AML market.